Selective benzopyranone and pyrimido[2,1-α]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: Synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro

Journal of Medicinal Chemistry

Volumn 48, Issue 2, 2005, Pages 569-585

  Griffin, Roger J ^a   Fontana, Gabriele ^a   Golding, Bernard T ^a   Guiard, Sophie ^a   Hardcastle, Ian R ^a   Leahy, Justin J J ^a   Martin, Niall ^b   Richardson, Caroline ^b   Rigoreau, Laurent ^a,b   Stockley, Martin ^a   Smith, Graeme C M ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b KuDOS Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 METHYLMORPHOLIN 4 YL)BENZ[H]CHROMEN 4 ONE; 7,8 BENZOCHROMEN 4 ONE; ATM PROTEIN; ATR PROTEIN; BENZOPYRAN DERIVATIVE; BENZOPYRANONE DERIVATIVE; CHROMENE DERIVATIVE; COUMARIN; DNA DEPENDENT PROTEIN KINASE; FLAVONE; ISOQUINOLINE DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; NU 7163; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; PYRIMIDO[2,1-A]ISOQUINOLIN 4 ONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIZATION; DRUG SYNTHESIS; ENZYME INHIBITION; HELA CELL; HUMAN; HUMAN CELL; IC 50; IONIZING RADIATION; PHARMACOPHORE; RADIOSENSITIZATION; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

BENZOPYRANS; CHROMONES; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HUMANS; ISOQUINOLINES; MORPHOLINES; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 19944432425     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049526a     Document Type: Article

References (40)

1. Hansen, W. K.; Kelley, M. R. Review of mammalian DNA repair and translational implications J. Pharmacol. Exp. Ther. 2000, 295, 1-9.
2. Chaney, S. G.; Sancar, A. DNA repair: Enzymatic mechanisms and relevance to drug response. J. Natl. Cancer. Inst. 1996, 88, 1346-1360.
3. Jackson, S. P. Sensing and repairing DNA double-strand breaks. Carcinogenesis 2002, 23, 687-696.
4. Smith, G. C. M.; Jackson, S. P. The DNA-dependent protein kinase. Genes Dev. 1999, 13, 916-934.
5. Gottleib, T. M.; Jackson, S. P. The DNA-dependent protein kinase requirement for DNA ends and association with Ku antigen. Cell 1993, 72, 131-142.
6. Yaneva, M.; Kowalewski, T.; Leiber, M. R. Interaction of DNA-dependent protein kinase with DNA and with Ku: Biochemical and atomic force microscopy studies. EMBO J. 1997, 16, 5098-5112.
7. Hammarstan, O.; Chu, G. DNA-dependent protein kinase: DNA binding and activation in the absence of Ku. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 525-530.
8. Ma, Y.; Pannicke, U.; Schwarz, K.; Lieber, M. R. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 2002, 108, 781-94.
9. Critchlow, S. E.; Jackson, S. P. DNA end joining: From yeast to man. Trends Biochem. Sci. 1998, 23, 394-398.
10. Kurimasa, A.; Kumano, S.; Boubnov, N. V.; Story, M. D.; Tung, C. S.; Peterson, S. R.; Chen, D. J. Requirement for the kinase activity of human DNA-dependent protein kinase catalytic subunit in DNA strand break rejoining. Mol. Cell. Biol. 1999, 19, 3877-3884.
11. Hartley, K. O.; Cell, D.; Smith, G. C. M.; Zhang, H.; Divecha, N.; Connelly, M. A.; Admon, A.; Lees-Miller, S. P.; Anderson, C. W.; Jackson, S. P. DNA-dependent protein kinase catalytic subunit: A relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product. Cell 1995, 82, 849-56.
12. Smith, G. C. M.; Jackson, S. P. The PIKK family of protein kinases. In Handbook of Cell Signaling, Vol 1; Elsevier Academic Press: New York, 2003; pp 557-561.
13. Shiloh, Y. ATM and related protein kinases: Safeguarding genome integrity. Nature Rev. Cancer 2003, 3, 155-168.
14. Zakian, V. A. ATM related genes: What do they tell us about functions of the human gene? Cell 1995, 82, 685-687.
15. Hunter, T. When is a lipid kinase not a lipid kinase? When it is a protein kinase. Cell 1995, 83, 1-4.
16. Powis, G.; Bonjouklian, R.; Berggren, M. M.; Gallegos, A.; Abraham, R.; Ashendel, C.; Zalkow, L.; Matter, W. F.; Dodge, J.; Grindey, G.; Vlahos, C. J. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res. 1994, 54, 2419-2423.
17. Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F. A specific inhibitor of phosphatidyl 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran- 4-one (LY294002). J. Biol. Chem. 1994, 269, 5241-5248.
18. Roma, G.; Di Braccio, M.; Grossi, G.; Marzano, C.; Simonato, M.; Bordin, F. Pyran derivatives XX. 2-Aminochromone benzo-fused derivatives with antiproliferative properties. Il Pharmaco 1998, 494-503.
19. Izzard, R. A.; Jackson, S. P.; Smith, G. C. M. Competitive and Noncompetitive Inhibition of the DNA-dependent Protein Kinase. Cancer Res. 1999, 59, 2581-2586.
20. Sarkaria, J. N.; Tibbetts, R. S.; Busby, E. C.; Kennedy, A. P.; Hill, D. E.; Abraham, R. T. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 1998, 58, 4375-4382.
21. Price, B. D.; Youmell, M. B. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res. 1995, 56, 246-250.
22. Rosenzweig, K. E.; Youmell, M. B.; Palayoor, S. T.; Price, B. D. Radiosensitization of human tumor cells by the phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin. Cancer Res. 1997, 3, 11149-1156.
23. Boulton, S.; Kyle, S.; Yalcintepe, L.; Durkacz, B. W. Wortmannin is a potent inhibitor of DNA double strand break but not single strand break repair in Chinese hamster ovary cells. Carcinogenesis 1997, 17, 22285-2290.
24. Griffin, R. J.; Calvert, A. H.; Curtin, N. J.; Durkacz, B. W.; Golding, B. T.; Hardcastle, I. R.; Leahy, J.; Martin, N.; Newell, D. R.; Rigoreau, L.; Smith, G. C. M.; Stockley, M.; Veuger, S.; Hickson, I. Structure-activity relationships and cellular activity of chromenone and pyrimidoisoquinoline inhibitors of DNA-dependent protein kinase (DNA-PK). Proc. Am. Assoc. Cancer Res. 2002, 43, 4210.
25. Morris, J.; Wishka, D. G.; Fang, Y. A cyclodehydration route to 2-aminochromones. Synth. Commun. 1994, 24, 849-858.
26. Boyd, J.; Roberson, A. The chemistry of the 'insoluble red' woods. Part II. A new synthesis of 4-hydroxycoumarins. J. Chem. Soc. 1948, 174-176.
27. Oh, C.; Yi, I.; Park, K. P. Nucleophilic vinylic substitution of halocoumarins and halo-1,4-naphthoquinones with morpholine. J. Heterocycl. Chem. 1994, 31, 841-845.
28. Di Braccio, M.; Grossi, G.; Roma, G.; Signorello, M. G.; Leoncini, G. Synthesis and in vitro inhibitory activity on human platelet aggregation of novel properly substituted 4-(1-piperazinyl)-coumarins. Eur. J. Med. Chem. 2004, 397-409.
29. (a) Baker, W. Molecular rearrangement of some o-acyloxyacetophenones and the mechanism of the production of 3-acyl-chromones. J. Chem. Soc. 1933, 1381-1388.
30. (b) Mahal, H. S.; Venkataraman, K. Synthetical experiments in the chromone group. Part XIV. The action of sodamide on 1-acyloxy-2-acetonaphthones. J. Chem. Soc. 1934, 1767-1769.
31. Springsteel, M. F.; Galietta, L. J. V.; Ma, T.; By, K; Berger, G. O.; Yang, H.; Dicus, C. W.; Choung, W.; Quan, C.; Shelat, A. A.; Guy, R. K.; Verkman, A. S.; Kurth, M. J.; Nantz, M. H. Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: Towards a pharmacophore model for the nucleotide-binding domain. Bioorg. Med. Chem. 2003, 11, 4113-4120.
32. Snyder, H. R.; Robison, M. M. Structure and reactions of malonyl-α-aminopyridine. I. J. Am. Chem. Soc. 1952, 74, 4910-4916.
33. Roma, G.; Cinone, N.; Di Braccio, M.; Grossi, G.; Leoncini, G.; Signorello, M. G.; Carotti, A. Synthesis, antiplatelet activity and comparative molecular field analysis of substituted 2-amino-4H-pyridopyrimidin-4-ones, their congeners and isosteric analogues. Bioorg. Med. Chem. 2000, 8, 751-768, and references therein.
34. Nutley, B. P.; Raynaud, F. I.; Hayes, A.; Goddard, P.; Jarman, M.; Workman, P. Pharmacokinetics and metabolism of the phosphatidylinositol 3-kinase inhibitor LY294002 in the mouse. Proc. Am. Assoc. Cancer Res. 2002, 42, 2044.
35. Walker, E. H.; Pacold, M. E.; Perisic, O.; Stephens, L.; Hawkins, P. T.; Wymann, M. P.; Williams, R. L. Structural determinations of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, And staurosporine. Mol. Cell 2000, 6, 909-919.
36. Veuger, S. J.; Curtin, N. J.; Richardson, C. J.; Smith, G. C. M.; Durkacz, B. W. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res. 2003, 63, 6008-6015.
37. Willmore, E.; de Caux, S.; Sunter, N. J.; Tilby, M. J.; Jackson, G. H.; Austin, C. A.; Durkacz, B. W. A novel DNA-dependent protein kinase inhibitor NU7026 potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukaemia. Blood, 2004, 103, 4659-4665.
38. Banin, S.; Moyal, L.; Shieh, S.; Taya, Y.; Anderson, C. W.; Chessa, L.; Smorodinsky, N. I.; Prives, C.; Reiss, Y.; Shiloh, Y.; Ziv, Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998, 281, 1674-1677.
39. Tibbetts, R. S.; Brumbaugh, K. M.; Williams, J. M.; Sarkaria, J. N.; Cliby, W. A.; Shieh, S. Y.; Taya, Y.; Prives, C.; Abraham, R. T. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 1999, 13, 152-157.
40. Brunn, G. J.; Williams, J.; Sabers, C.; Wiederrecht, G.; Lawrence, J. C.; Abraham, R. T. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 1996, 15, 5256-5267.